Novo Nordisk A/S (NYSE:NVO) Shares Sold by Consolidated Planning Corp

Consolidated Planning Corp lowered its position in Novo Nordisk A/S (NYSE:NVO) by 11.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,796 shares of the company’s stock after selling 6,338 shares during the quarter. Consolidated Planning Corp’s holdings in Novo Nordisk A/S were worth $4,197,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $28,000. Capital Performance Advisors LLP acquired a new stake in Novo Nordisk A/S during the 3rd quarter valued at $42,000. Carolina Wealth Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the third quarter worth $48,000. Dunhill Financial LLC lifted its position in shares of Novo Nordisk A/S by 196.8% in the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after acquiring an additional 311 shares in the last quarter. Finally, Albion Financial Group UT boosted its stake in shares of Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after acquiring an additional 278 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on NVO. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday. They issued an “equal weight” rating for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, BMO Capital Markets reduced their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Price Performance

NVO stock opened at $81.78 on Thursday. The company has a market cap of $366.99 billion, a PE ratio of 24.86, a price-to-earnings-growth ratio of 0.96 and a beta of 0.45. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62. The stock has a 50-day moving average price of $90.45 and a two-hundred day moving average price of $110.60. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, research analysts predict that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is currently 21.88%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.